Go to PegaPoll
PEGAPOLL · NEWS

Novo trial finds Wegovy lowers BMI in obese children aged 6 to 11

CNBC Top News · 2026-11-16
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.

Novo on Monday published full late-stage data showing Wegovy cut weight in obese children aged 6 to under 12 over 68 weeks. Among those who stayed on drug, BMI fell an estimated 19.7 percentage points versus placebo (17.4% vs a 2.2% rise); including dropouts, the advantage was 16.2 points. All 167 children also received diet and exercise support. Wegovy is approved for ages 12 and older but not for younger children.

Continue in the app — vote & join in ➔
Source: CNBC Top News · via ahirlevel.hu

Related news